• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Max Planck Institute for Infection Biology

Headquarters: Berlin, Germany
Website: http://www.mpiib-berlin.mpg.de...
Year Founded: 1992
Status: N/A

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Feb 7, 2020
Translation in Brief

Gilead’s remdesivir vs. 2019-nCov in cells; plus Syndax, Syntrix and Max Planck

BioCentury's roundup of preclinical news
Read More
BioCentury | Jan 31, 2020
Distillery Therapeutics

Inhibiting SPK2 to treat Middle East respiratory syndrome

Read More
BioCentury | Jan 28, 2020
Emerging Company Profile

Quenching the flames of inflammatory cell death

With a $50M round, Quench is developing first-in-class gasdermin D inhibitors to treat inflammatory diseases.
Read More
BioCentury | Mar 19, 2019
Regulation

Talk less, do more: Germline gene editing needs real plans, not just moratoria

Editor's Commentary: Why the international community should fund, coordinate labs for safe use of germline gene editing
Read More
BioCentury | Mar 13, 2019
Politics & Policy

Researchers call for global moratorium, not outright ban, on germline editing

Read More
BioCentury | Jan 15, 2019
Distillery Therapeutics

Cancer

Read More
BioCentury | Oct 4, 2018
Tools & Techniques

No crisp upper hand in CRISPR

What the most recent CRISPR ruling means for companies looking to access the IP
Read More
BioCentury | Sep 13, 2018
Preclinical News

Paper-based method for POC metabolite diagnosis

Read More
BioCentury | Aug 28, 2018
Preclinical News

Stealth start-up Quench among teams tying protein to inflammatory cell death

Read More
BioCentury | May 9, 2018
Distillery Therapeutics

Otologic

Read More
Items per page:
1 - 10 of 38